Drug Profile
STP06 1002
Alternative Names: STP06-1002; STP1002Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Korea Research Institute of Chemical Technology; ST Pharm
- Class Antineoplastics; Small molecules
- Mechanism of Action Tankyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Colorectal cancer
Most Recent Events
- 14 Apr 2023 Preclinical development in Colorectal-cancer in South Korea (PO) .
- 14 Apr 2023 Pharmacodynamics data from a preclincial trial in colorectal cancer presented at the 114th Annual Meeting of the American Association for Cancer Research
- 30 Mar 2023 ST Pharm completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in USA (PO) (NCT04505839)